{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=20%25+subcutaneous+immunoglobulin&page=4", "query": { "intervention": "20% subcutaneous immunoglobulin", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 128, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=20%25+subcutaneous+immunoglobulin&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=20%25+subcutaneous+immunoglobulin&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T23:39:27.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00092222", "title": "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder", "HHV-8", "Malignancy", "HIV" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Observation Only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-10-28", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092222" }, { "nct_id": "NCT03168100", "title": "2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2017-10-01", "completion_date": "2019-01-24", "has_results": false, "last_update_posted_date": "2019-01-28", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03168100" }, { "nct_id": "NCT02384954", "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-04-17", "completion_date": "2020-12-13", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 4, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02384954" }, { "nct_id": "NCT01087762", "title": "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondyloarthropathies" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087762" }, { "nct_id": "NCT01058005", "title": "Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "BG00002 (natalizumab)", "type": "DRUG" }, { "name": "interferon beta-1a", "type": "DRUG" }, { "name": "glatiramer acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 84, "start_date": "2010-03", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2014-09-03", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 19, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Maitland", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01058005" }, { "nct_id": "NCT01920477", "title": "Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus Vulgaris" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2013-08-13", "completion_date": "2018-01-11", "has_results": true, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 7, "location_summary": "Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920477" }, { "nct_id": "NCT02130882", "title": "Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Respiratory System Agents", "Anti-Asthmatic Agents", "Hematologic Diseases", "Leukocyte Disorders", "Hypereosinophilia" ], "interventions": [ { "name": "benralizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2014-05-19", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02130882" }, { "nct_id": "NCT04566692", "title": "A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "IGSC 20%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2020-11-24", "completion_date": "2022-07-25", "has_results": true, "last_update_posted_date": "2023-09-29", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "North Palm Beach", "state": "Florida" }, { "city": "Albany", "state": "Georgia" }, { "city": "Chevy Chase", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566692" }, { "nct_id": "NCT02613910", "title": "Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pemphigus" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Acetaminophen/paracetamol", "type": "DRUG" }, { "name": "Antihistamine (cetirizine or equivalent)", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2015-12-23", "completion_date": "2016-03-23", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 2, "location_summary": "Los Angeles, California • Ann Arbor, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02613910" }, { "nct_id": "NCT03828019", "title": "Adalimumab vs. Conventional Immunosuppression for Uveitis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uveitis" ], "interventions": [ { "name": "Adalimumab (ADA)", "type": "BIOLOGICAL" }, { "name": "Conventional immunosuppression (CON)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "JHSPH Center for Clinical Trials", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 227, "start_date": "2019-09-16", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-09T23:39:27.432Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03828019" } ] }